Evidence map›Paper›PMID 34104480›Full record

ArticleScars, burns & healing

Mortality incidence among critically ill burn patients infected with multidrug-resistant organisms: A retrospective cohort study.

Moustafa Ellithy, Hassan Mitwally, Mohamed Saad, Ranjan Mathias, Adila Shaukat, Hani Elzeer, Sunil Hassan Koya, Zia Mahmood, Khaled Gazwi

Open access · goldAbstract read
In one paragraph

Article in Scars, burns & healing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Infection and Burn Injury.European burn journal · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Moustafa EllithyDepartment of Critical Care, Hazm Mebaireek General Hospital, Hamad Medical Corporation, Doha, Qatar.
Hassan MitwallyDepartment of Pharmacy, Al-Wakra-Hospital, Hamad Medical Corporation, Doha, Qatar.ORCID https://orcid.org/0000-0002-5309-8641
Mohamed SaadDepartment of Pharmacy, Al-Wakra-Hospital, Hamad Medical Corporation, Doha, Qatar.
Ranjan MathiasDepartment of Anesthesiology/Critical Care, Al-Wakra-Hospital, Hamad Medical Corporation, Doha, Qatar.
Adila ShaukatDepartment of Medicine-Infectious Diseases, Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Hani ElzeerCritical Care Departement, Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Sunil Hassan KoyaCritical Care Departement, Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Zia MahmoodDepartment of Anesthesiology/Critical Care, Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Khaled GazwiCritical Care Departement, Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Hamad Medical Corporation · QAHamad General Hospital · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMany risk factors have been reported to increase mortality among burn patients. Previously, a higher mortality incidence was reported in acute burn patients infected with multidrug-resistant organisms (MDROs) when compared to patients infected with non-MDROs. However, considering this as an independent risk factor for mortality in acute burn patients is not yet confirmed.

methodsWe conducted an observational retrospective study in Qatar. We included adult patients admitted to the surgical intensive care unit (ICU) between January 2015 and December 2017 with burn injuries involving either at least 15% of the total body surface area (TBSA) or less than 15% with facial involvement. All patients developed infection with a positive culture of either MDRO or non-MDRO. The primary outcome was in-hospital mortality. Other outcomes included days of mechanical ventilation, ICU, length of stay in hospital, and requirement of vasoactive agents.

resultsFifty-eight patients were included in the final analysis: 33 patients in the MDRO group and 25 patients in the non-MDRO group. Six patients (18.2%) died in the MDRO group versus four patients (16%) in the non-MDRO group (

conclusionIn severely burned patients, infection with MDRO was not associated with increased mortality. There was a trend towards increased hospitalisation in MDRO-infected patients. Further studies with a larger sample size are needed to confirm these results. LAY SUMMARY: Many factors affect mortality in burn patients admitted to the intensive care unit, such as age, total body surface area involved in the injury, and others. In this retrospective study, we evaluated whether wound infection with a bacterial organism resistant to multiple classes of antibiotics (multidrug-resistant) is considered an independent risk factor for mortality in critically ill burn patients. We included 58 patients requiring intensive care admission with burn injuries involving 15% or more of the total body surface area or less than 15% but with facial involvement. A total of 33 patients were infected with multidrug-resistant organisms (MDROs) and 25 patients with non-MDROs. Six patients (18.2%) from the MDRO group died versus four (16%) in the non-MDRO group. The MDRO group required a longer stay in hospital and an average of one more day on a mechanical ventilator. We concluded that wound infection with MDROs might not increase mortality when compared to wound infection with non-MDROs, although other studies with a larger number of patients involved need to be conducted to validate these results.

Indexed as

Burnsinfectionintensive care unitmortalitymultidrug resistance

Identifiers

PMID34104480
PMCPMC8155764
OpenAlexW3164121210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.